Tetradrip Pharma Profile
Key Indicators
- Authorised Capital ₹ 12.00 Cr
as on 28-07-2024
- Paid Up Capital ₹ 6.19 Cr
as on 28-07-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.23 Cr
as on 28-07-2024
- Revenue 507.63%
(FY 2023)
- Profit 104.45%
(FY 2023)
- Ebitda -52.39%
(FY 2023)
- Net Worth 18.49%
(FY 2023)
- Total Assets 6.85%
(FY 2023)
About Tetradrip Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 12.00 Cr and a paid-up capital of Rs 6.19 Cr.
The company currently has active open charges totaling ₹4.23 Cr.
Manoj Gupta and Swati Gupta serve as directors at the Company.
- CIN/LLPIN
U33111WB2013PTC192301
- Company No.
192301
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2013
- Date of AGM
31 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Burdwan, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tetradrip Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Gupta  | Director | 06-Dec-2019 | Current |
| Swati Gupta | Director | 06-Dec-2019 | Current |
Financial Performance of Tetradrip Pharma.
Tetradrip Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 507.63% increase. The company also saw a substantial improvement in profitability, with a 104.45% increase in profit. The company's net worth Soared by an impressive increase of 18.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tetradrip Pharma?
In 2023, Tetradrip Pharma had a promoter holding of 88.00% and a public holding of 12.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharma Impex Laboratories Pvt LtdActive 47 years 2 monthsManoj Gupta and Swati Gupta are mutual person
Mg Pharmaceuticals Private LimitedActive 28 years 21 daysManoj Gupta and Swati Gupta are mutual person
- Clinovation Research Private LimitedActive 12 years 5 months
Manoj Gupta and Swati Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Aug 2015 | ₹4.23 Cr | Open |
How Many Employees Work at Tetradrip Pharma?
Tetradrip Pharma has a workforce of 69 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tetradrip Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tetradrip Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
